What is MS Phase 3 Study Fingolimod FREEDOMS II?

Category: Others

true

Generic name: Fingolimod Clinical Trial

See also: Clinical Trial

NCT00355134 is a 24-month double-blind, randomized, study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. Other study names are ID#CFTY720D2309 and FREEDOMS II.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 1
None 2

Commonly reported side effects and conditions associated with MS Phase 3 Study Fingolimod FREEDOMS II

Side effect Patients
Flatulence 1

Why patients stopped taking MS Phase 3 Study Fingolimod FREEDOMS II

Multiple reasons could be selected

Reason Patients
Did not seem to work 1
See all 2 patients who've stopped using MS Phase 3 Study Fingolimod FREEDOMS II

Duration

Stopped using MS Phase 3 Study Fingolimod FREEDOMS II

Duration Patients
6 months - 1 year 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 3
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 2
Not at all hard to take 1
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 1
Last updated:

1 patient evaluation for MS Phase 3 Study Fingolimod FREEDOMS II

Jan 24, 2011 (Started Oct 27, 2008)

  • Effectiveness
    Can't tell (for transplant rejection prevention)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Advice & Tips: Trial from Oct 08-Jan 11. Easy oral med to take (no shots!). Little to no side effects.
Cost: < $25 monthly

Nov 8, 2010 (Started Oct 27, 2008)

  • Effectiveness
    Major (for multiple sclerosis)
  • Side effects
    None
  • Adherence
    Always
  • Burden
    A little hard to take
Dosage: 0.5 mg Daily
Cost: < $25 monthly

  • 0 helpful marks
Last updated:
Showing 1 of 1 patient evaluation for MS Phase 3 Study Fingolimod FREEDOMS II